AU8071698A - Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction - Google Patents
Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transductionInfo
- Publication number
- AU8071698A AU8071698A AU80716/98A AU8071698A AU8071698A AU 8071698 A AU8071698 A AU 8071698A AU 80716/98 A AU80716/98 A AU 80716/98A AU 8071698 A AU8071698 A AU 8071698A AU 8071698 A AU8071698 A AU 8071698A
- Authority
- AU
- Australia
- Prior art keywords
- relatedcellular
- modulation
- signal transduction
- protein tyrosine
- heteroaryl compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000019491 signal transduction Effects 0.000 title 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4956097P | 1997-06-13 | 1997-06-13 | |
| US60049560 | 1997-06-13 | ||
| PCT/US1998/012333 WO1998056376A1 (en) | 1997-06-13 | 1998-06-12 | Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU8071698A true AU8071698A (en) | 1998-12-30 |
Family
ID=21960475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU80716/98A Abandoned AU8071698A (en) | 1997-06-13 | 1998-06-12 | Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1007042A4 (en) |
| JP (1) | JP2002512628A (en) |
| AU (1) | AU8071698A (en) |
| CA (1) | CA2293400A1 (en) |
| WO (1) | WO1998056376A1 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6316635B1 (en) | 1995-06-07 | 2001-11-13 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| US6147106A (en) | 1997-08-20 | 2000-11-14 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
| US6486185B1 (en) | 1997-05-07 | 2002-11-26 | Sugen, Inc. | 3-heteroarylidene-2-indolinone protein kinase inhibitors |
| US6316429B1 (en) | 1997-05-07 | 2001-11-13 | Sugen, Inc. | Bicyclic protein kinase inhibitors |
| AU3363599A (en) * | 1998-03-26 | 1999-10-18 | Max-Planck Institut Fur Biochemie | Heterocyclic families of compounds for the modulation of tyrosine protein kinase |
| US6514981B1 (en) | 1998-04-02 | 2003-02-04 | Sugen, Inc. | Methods of modulating tyrosine protein kinase function with indolinone compounds |
| EP1082305A4 (en) | 1998-05-29 | 2001-09-26 | Sugen Inc | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| US6689806B1 (en) | 1999-03-24 | 2004-02-10 | Sugen, Inc. | Indolinone compounds as kinase inhibitors |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| HUP0202708A3 (en) | 1999-04-15 | 2004-12-28 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use |
| NZ517426A (en) | 1999-08-27 | 2004-04-30 | Sugen Inc | Phosphate mimics and methods of treatment using phosphatase inhibitors |
| US6878733B1 (en) | 1999-11-24 | 2005-04-12 | Sugen, Inc. | Formulations for pharmaceutical agents ionizable as free acids or free bases |
| MY130363A (en) | 2000-02-15 | 2007-06-29 | Sugen Inc | "pyrrole substituted 2-indolinone protein kinase inhibitors" |
| AR042586A1 (en) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE |
| PE20030008A1 (en) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | DUAL INHIBITORS OF PDE 7 AND PDE 4 |
| US6933303B2 (en) | 2001-10-19 | 2005-08-23 | Transtech Pharma, Inc. | Heteroaryl-fused nitrogen heterocycles as therapeutic agents |
| TWI283670B (en) * | 2001-11-28 | 2007-07-11 | Sod Conseils Rech Applic | 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as a medicament |
| US7049333B2 (en) | 2002-06-04 | 2006-05-23 | Sanofi-Aventis Deutschland Gmbh | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis |
| US7141596B2 (en) | 2003-10-08 | 2006-11-28 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
| US7521473B2 (en) | 2004-02-25 | 2009-04-21 | Wyeth | Inhibitors of protein tyrosine phosphatase 1B |
| EP3390387B1 (en) | 2015-12-18 | 2021-11-17 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
| WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
| CN116478131A (en) | 2016-07-12 | 2023-07-25 | 锐新医药公司 | 2, 5-disubstituted and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors |
| AR110282A1 (en) | 2016-12-02 | 2019-03-13 | Hoffmann La Roche | BICYCLIC AMIDA COMPOUNDS AND USE OF THESE IN THE TREATMENT OF DISEASES MEDIATED BY RIP1 |
| CN110446709B (en) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | Bicyclic compounds as allosteric SHP2 inhibitors |
| EP4230623A3 (en) * | 2017-01-23 | 2023-10-11 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| PT3652178T (en) | 2017-07-14 | 2024-03-18 | H Hoffnabb La Roche Ag | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF |
| MX2020002608A (en) | 2017-09-07 | 2020-09-18 | Revolution Medicines Inc | Shp2 inhibitor compositions and methods for treating cancer. |
| MX2020003439A (en) | 2017-10-11 | 2020-07-29 | Hoffmann La Roche | Bicyclic compounds for use as rip1 kinase inhibitors. |
| EP3694848A1 (en) | 2017-10-12 | 2020-08-19 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| CR20200168A (en) * | 2017-10-31 | 2020-07-12 | Hoffmann La Roche | Bicyclic sulfones and sulfoxides and methods of use thereof |
| AU2018385713A1 (en) | 2017-12-15 | 2020-06-18 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric SHP2 inhibitors |
| CR20240382A (en) | 2018-05-01 | 2025-08-29 | Revolution Medicines Inc | C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors |
| WO2020146615A1 (en) | 2019-01-11 | 2020-07-16 | Genentech, Inc. | Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof |
| WO2022061224A1 (en) | 2020-09-21 | 2022-03-24 | Landos Biopharma, Inc. | Nlrx1 ligands |
| CN120004879A (en) * | 2025-02-14 | 2025-05-16 | 中国药科大学 | A class of compounds containing thioether skeleton structure and their application in the preparation of phosphoglycerate dehydrogenase inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| US5798374A (en) * | 1995-06-07 | 1998-08-25 | Sugen Inc. | Methods of inhibiting phosphatase activity and treatment of disorders associated therewith |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
-
1998
- 1998-06-12 WO PCT/US1998/012333 patent/WO1998056376A1/en not_active Ceased
- 1998-06-12 JP JP50329999A patent/JP2002512628A/en active Pending
- 1998-06-12 AU AU80716/98A patent/AU8071698A/en not_active Abandoned
- 1998-06-12 CA CA002293400A patent/CA2293400A1/en not_active Abandoned
- 1998-06-12 EP EP98929059A patent/EP1007042A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998056376A1 (en) | 1998-12-17 |
| EP1007042A4 (en) | 2001-07-04 |
| JP2002512628A (en) | 2002-04-23 |
| CA2293400A1 (en) | 1998-12-17 |
| EP1007042A1 (en) | 2000-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU8071698A (en) | Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction | |
| AU5468499A (en) | 3-methylidenyl-2-indolinone modulators of protein kinase | |
| AU2804597A (en) | Synthesis of fluorophore-labeled dna | |
| AU2713799A (en) | Modulators of protein tyrosine phosphatases (ptpases) | |
| AU1529997A (en) | Substituted histidine inhibitors of protein farnesyltransferase | |
| AU2713699A (en) | Modulators of protein tyrosine phosphatases (ptpases) | |
| AU7398194A (en) | Oligonucleotide modulation of protein kinase c | |
| AU3363599A (en) | Heterocyclic families of compounds for the modulation of tyrosine protein kinase | |
| AU2805897A (en) | Inhibitors of protein farnesyltransferase | |
| AU6411698A (en) | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors | |
| AU4583796A (en) | Determination of software functionality | |
| AU5710398A (en) | Thiazole compounds and methods of modulating signal transduction | |
| AU7289696A (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
| AU3693697A (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
| AU3443997A (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
| AU2825899A (en) | Modulators of protein tyrosine phosphatases (ptpases) | |
| AU1381499A (en) | Cell-permeable protein inhibitors of calpain | |
| AU8508798A (en) | Polymerization of olefins | |
| AU3482493A (en) | Novel protein tyrosine kinases | |
| AU7622698A (en) | Use of indolinone compounds as modulators of protein kinases | |
| AU3549397A (en) | Over-expression of proteins | |
| AU4367196A (en) | Novel protein domain which binds tyrosine phosphorylated proteins | |
| AU6250298A (en) | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones | |
| AU2217797A (en) | Synthesis of indolylmaleimides | |
| AU4157097A (en) | Synthesis of bisindolylmalimides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |